InvestorsObserver
×
News Home

Should Capricor Therapeutics Inc (CAPR) be in Your Portfolio?

Wednesday, September 23, 2020 10:50 AM | InvestorsObserver Analysts

Mentioned in this article

Should Capricor Therapeutics Inc (CAPR) be in Your Portfolio?

Capricor Therapeutics Inc (CAPR) is near the top in its industry group according to InvestorsObserver. CAPR gets an overall rating of 65. That means it scores higher than 65 percent of stocks. Capricor Therapeutics Inc gets a 83 rank in the Biotechnology industry. Biotechnology is number 31 out of 148 industries.

Overall Score - 65
CAPR has an Overall Score of 65. Find out what this means to you and get the rest of the rankings on CAPR!

What do These Ratings Mean?

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

What's Happening With Capricor Therapeutics Inc Stock Today?

Capricor Therapeutics Inc (CAPR) stock is up 7.34% while the S&P 500 is unchanged 0% as of 10:47 AM on Wednesday, Sep 23. CAPR has risen $0.39 from the previous closing price of $5.31 on volume of 1,371,190 shares. Over the past year the S&P 500 has gained 11.76% while CAPR has risen 88.12%. CAPR lost -$1.30 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Capricor Therapeutics Inc (CAPR) Stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App